Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone

<b>Background/Objectives</b>: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. <b>Methods</b>: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105-137 ± 2 dGA, <i>n</i> = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; <i>n</i> = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105-137 ± 2 dGA; <i>n</i> = 17) or Dex and MitoQ (Dex+MitoQ; <i>n</i> = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. <b>Results</b>: Dex decreased the hepatic activity of fetal CYP3A (-56%, <i>P</i><sub>Dex</sub> = 0.0322), and 9 mo lamb CYP1A2 (-22%, <i>P</i><sub>Dex</sub> = 0.0003), CYP2B6 (-36%, <i>P</i><sub>Dex</sub> = 0.0234), CYP2C8 (-34%, <i>P</i><sub>Dex</sub> = 0.0493) and CYP2E1 (-57%, <i>P</i><sub>Dex</sub> = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, <i>P</i><sub>MitoQ</sub> = 0.0011) and CYP3A (midazolam, +25%, <i>P</i><sub>MitoQ</sub> = 0.0162) and increased CAT expression (<i>P</i><sub>MitoQ</sub> = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, <i>P</i><sub>Intx</sub> < 0.0003), decreased CYP1A2 activity (-14%, <i>P</i><sub>Intx</sub> = 0.0036) and decreased mitochondrial abundance (<i>P</i><sub>Intx</sub> = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (<i>P</i><sub>Dex</sub> = 0.0055, <i>P</i><sub>MitoQ</sub> = 0.0006 and <i>P</i><sub>Intx</sub> = 0.0034). <b>Conclusions</b>: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2025-02-22
DOI
https://doi.org/10.3390/pharmaceutics17030285
Citations
2
Primary Topic
Neonatal Respiratory Health Research
Type
article
Field-Weighted Citation Impact
3.04

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone

Youguo Niu, Janna Leigh Morrison, Michael D. Wiese, Ashley S. Meakin et al.
2 citations
Pharmaceutics
Neonatal Respiratory Health Research
3.04
article

Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone

Youguo Niu, Janna Leigh Morrison, Michael D. Wiese, Ashley S. Meakin, Dino A. Giussani, Michael Bennett, Sage G. Ford, Michael P. Murphy, Kimberley J. Botting‐Lawford
article en
2 citations

Abstract

<b>Background/Objectives</b>: In pregnancy threatened by preterm birth, antenatal corticosteroids (ACS) are administered to accelerate fetal lung maturation. However, they have side effects, including the production of reactive oxygen species that can impact cytochrome P450 (CYP) activity. We hypothesised that antioxidants could protect a fetus treated with ACS during gestation and prevent the programming of altered hepatic CYP activity in the offspring. The primary outcome of our study was the impact of different maternal treatments on the activity of hepatic drug-metabolising enzymes in offspring. <b>Methods</b>: At 100 ± 1 days gestational age (dGA, term = 147 dGA), 73 ewes were randomly allocated to the following: saline (5 mL IV daily 105-137 ± 2 dGA, <i>n</i> = 17), ACS (Dexamethasone (Dex); 12 mg IM at 115 and 116 dGA; <i>n</i> = 25), MitoQ (6 mg/kg MS010 IV, daily bolus 105-137 ± 2 dGA; <i>n</i> = 17) or Dex and MitoQ (Dex+MitoQ; <i>n</i> = 14). CYP activity and protein abundance were assessed using functional assays and Western blot. <b>Results</b>: Dex decreased the hepatic activity of fetal CYP3A (-56%, <i>P</i><sub>Dex</sub> = 0.0322), and 9 mo lamb CYP1A2 (-22%, <i>P</i><sub>Dex</sub> = 0.0003), CYP2B6 (-36%, <i>P</i><sub>Dex</sub> = 0.0234), CYP2C8 (-34%, <i>P</i><sub>Dex</sub> = 0.0493) and CYP2E1 (-57%, <i>P</i><sub>Dex</sub> = 0.0009). For all, except CYP1A2, activity returned to control levels with Dex+MitoQ in 9 mo lambs. In 9 mo lambs, MitoQ alone increased activity of CYP2B6 (+16%, <i>P</i><sub>MitoQ</sub> = 0.0011) and CYP3A (midazolam, +25%, <i>P</i><sub>MitoQ</sub> = 0.0162) and increased CAT expression (<i>P</i><sub>MitoQ</sub> = 0.0171). Dex+MitoQ increased CYP3A4/5 activity (testosterone, +65%, <i>P</i><sub>Intx</sub> < 0.0003), decreased CYP1A2 activity (-14%, <i>P</i><sub>Intx</sub> = 0.0036) and decreased mitochondrial abundance (<i>P</i><sub>Intx</sub> = 0.0051). All treatments decreased fetal hepatic DRP1, a regulator of mitochondrial fission (<i>P</i><sub>Dex</sub> = 0.0055, <i>P</i><sub>MitoQ</sub> = 0.0006 and <i>P</i><sub>Intx</sub> = 0.0034). <b>Conclusions</b>: Antenatal Dex reduced activity of only one CYP in the fetus but programmed the reduced activity of several hepatic CYPs in young adult offspring, and this effect was ameliorated by combination with MitoQ.

PharmaceuticsVol. 17(3)
University of South Australia (AU), University of Cambridge (GB), MRC Mitochondrial Biology Unit (GB)
British Heart Foundation, Australian Research Council
Good health and well-being
Openalex Percentile: Top 11%
Neonatal Respiratory Health Research
3.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.